Amy ChandlerSkerkis - First Wave QA Affairs
| FWBIDelisted Stock | USD 0.61 0.03 4.69% |
Insider
Amy ChandlerSkerkis is QA Affairs of First Wave BioPharma
| Age | 55 |
| Phone | 561 589 7020 |
| Web | https://www.firstwavebio.com |
First Wave Management Efficiency
The company has return on total asset (ROA) of (0.2707) % which means that it has lost $0.2707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1528) %, meaning that it created substantial loss on money invested by shareholders. First Wave's management efficiency ratios could be used to measure how well First Wave manages its routine affairs as well as how well it operates its assets and liabilities.First Wave BioPharma currently holds 826.84 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. First Wave BioPharma has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about First Wave's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| David MD | LMF Acquisition Opportunities | N/A | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| M FACP | LMF Acquisition Opportunities | 51 | |
| JD MBA | Immix Biopharma | N/A | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| DSc MSE | Immix Biopharma | 75 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| MBA MD | Immix Biopharma | 49 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Caryl Baron | LMF Acquisition Opportunities | 57 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Gabriel BA | Immix Biopharma | 37 | |
| Gerald Proehl | Dermata Therapeutics | 65 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.27 |
First Wave BioPharma Leadership Team
Elected by the shareholders, the First Wave's board of directors comprises two types of representatives: First Wave inside directors who are chosen from within the company, and outside directors, selected externally and held independent of First. The board's role is to monitor First Wave's management team and ensure that shareholders' interests are well served. First Wave's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, First Wave's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James MD, Consultant | ||
| Jack Syage, COO President | ||
| Sarah CPA, Chief Officer | ||
| Amy ChandlerSkerkis, QA Affairs | ||
| RPh MBA, CEO President | ||
| Martin MBA, Senior Development |
First Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is First Wave a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 72.56 M | |||
| Shares Outstanding | 2.03 M | |||
| Shares Owned By Insiders | 5.66 % | |||
| Shares Owned By Institutions | 1.46 % | |||
| Number Of Shares Shorted | 46.6 K | |||
| Price To Book | 1.87 X | |||
| EBITDA | (15.74 M) | |||
| Net Income | (15.79 M) |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |